Aurinia Pharmaceuticals (AUPH) Total Liabilities (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Total Liabilities came in at $156.4 million in Q1 2026, up 1.11% YoY from $154.7 million in Q1 2025, and down 8.16% on a QoQ basis from $170.3 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Total Liabilities (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 11 years of Total Liabilities data on file, last reported at $156.4 million in Q1 2026.
- Quarterly Total Liabilities rose 1.11% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 1.11% YoY) and the FY2025 annual result came in at $170.3 million, down 1.68% from the prior year.
- Total Liabilities slipped to $156.4 million in Q1 2026, from $170.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $173.2 million in Q4 2024 to a low of $58.4 million in Q2 2022.
- A 5-year average of $132.9 million and a median of $157.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities soared 168.26% — and 2025, when it slipped 1.68%.
- Tracing AUPH's Total Liabilities over 5 years: stood at $65.4 million in 2022, then jumped by 160.0% to $170.1 million in 2023, then grew by 1.8% to $173.2 million in 2024, then dropped by 1.68% to $170.3 million in 2025, then fell by 8.16% to $156.4 million in 2026.
- The last three Total Liabilities figures came in at $156.4 million (Q1 2026), $170.3 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 177.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 177.40 Mn |
| Mar 31, 2026 | 156.37 Mn |
| Dec 31, 2025 | 170.26 Mn |
| Sep 30, 2025 | 161.76 Mn |
| Jun 30, 2025 | 167.26 Mn |
| Mar 31, 2025 | 154.66 Mn |
| Dec 31, 2024 | 173.17 Mn |
| Sep 30, 2024 | 161.36 Mn |
| Jun 30, 2024 | 158.91 Mn |
| Mar 31, 2024 | 157.16 Mn |
| Dec 31, 2023 | 170.11 Mn |
| Sep 30, 2023 | 163.14 Mn |
| Jun 30, 2023 | 156.61 Mn |
| Mar 31, 2023 | 61.35 Mn |
| Dec 31, 2022 | 65.43 Mn |
| Sep 30, 2022 | 64.87 Mn |
| Jun 30, 2022 | 58.38 Mn |
| Mar 31, 2022 | 58.78 Mn |
| Dec 31, 2021 | 64.28 Mn |
| Sep 30, 2021 | 61.89 Mn |